[CME/Answers: Giant Cell Arteritis]
Katrin Reiner1, Thomas Fehr1, Jürg Wick1,2
1Innere Medizin, Kantonsspital Graubünden, Chur.
Insights
Giant cell arteritis (GCA) is a common vasculitis in older adults, affecting large vessels. While steroids are standard, tocilizumab offers a safer, more effective treatment option for this condition.
Area of Science:
- Rheumatology
- Internal Medicine
- Vascular Medicine
Background:
- Giant cell arteritis (GCA) is the most prevalent vasculitis in individuals over 50.
- It primarily affects large blood vessels, leading to diverse symptoms.
- Potential complications include irreversible vision loss, underscoring the need for prompt diagnosis and management.
Purpose of the Study:
- To review the current understanding of Giant Cell Arteritis.
- To discuss diagnostic criteria and clinical manifestations.
- To evaluate treatment options, including standard and emerging therapies.
Main Methods:
- Literature review of existing studies and clinical trials.
- Analysis of treatment efficacy and safety profiles.
- Synthesis of current recommendations and guidelines.
Main Results:
- GCA presents with cranial or extra-cranial symptoms, ranging from headaches to systemic signs like fever and fatigue.
- Steroids have been the mainstay of treatment for decades but are associated with significant side effects.
- Tocilizumab has emerged as a more effective and safer therapeutic alternative.
Conclusions:
- Early diagnosis and treatment are crucial to prevent severe complications like vision loss in GCA.
- While steroids remain a common treatment, their adverse effects necessitate exploring alternatives.
- Tocilizumab shows promise as a superior treatment option for Giant Cell Arteritis.
Abstract:
CME/Answers: Giant Cell Arteritis Abstract. Giant cell arteritis (GCA) is the most common vasculitis among patients over the age of 50. Mainly large vessels are targeted. GCA can be differentiated into cranial and extra-cranial types; thus the symptoms can range from headache, blurred vision and jaw claudication to non-specific symptoms like fatigue, polymyalgia and fever. Complications such as an irreversible loss of vision are critical, which is why timeous diagnosis and treatment are essential. There are some recommendations for treatment, but no defined guidelines exist. Steroids have been the standard treatment for the past six decades and remain so, but side effects are common. Tocilizumab represents an alternative and more effective and safer treatment.
Related Concept Videos
Myocarditis III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Aneurysm III: Interprofessional Care
Myocarditis II: Clinical Features and Diagnostic Tests
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Myocarditis I: Introduction


